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Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment
options and very poor prognosis following progression after standard chemotherapeutic regimens. Therefore, novel
molecules and therapeutic options are urgently needed for this category of patients. Recently, we have identified
PAC as a curcumin analogue with potent anti-cancer features.
Methods: HPLC was used to evaluate the stability of PAC and curcumin in PBS and also in circulating blood.
Cytotoxicity/apoptosis was assessed in different breast cancer cell lines using propidium iodide/annexinV associated
with flow cytometry. Furthermore, immunoblotting analysis determined the effects of PAC on different oncogenic
proteins and pathways. Additionally, the real time xCELLigence RTCA technology was applied to investigate the
effect of PAC on the cellular proliferation, migration and invasion capacities.
Results: PAC is more stable than curcumin in PBS and in circulating blood. Furthermore, we have shown
differential sensitivity of estrogen receptor-alfa positive (ERα+) and estrogen receptor alfa negative (ERα−) breast
cancer cells to PAC, which down-regulated ERα in both cell types. This led to complete disappearance of ERα in
ERα− cells, which express very low level of this receptor. Interestingly, specific down-regulation of ERα in receptor
positive cells increased the apoptotic response of these cells to PAC, confirming that ERα inhibits PAC-dependent
induction of apoptosis, which could be mediated through ERα down-regulation. Additionally, PAC inhibited the
proliferation and suppressed the epithelial-to-mesenchymal transition process in breast cancer cells, with higher
efficiency on the TNBC subtype. This effect was also observed in vivo on tumor xenografts. Additionally, PAC
suppressed the expression/secretion of 2 important cytokines IL-6 and MCP-1, and consequently inhibited the
paracrine procarcinogenic effects of breast cancer cells on breast stromal fibroblasts.
Conclusion: These results indicate that PAC could be considered as important candidate for future therapeutic
options against the devastating TNBC subtype.
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Background
Despite advances in diagnosis and treatment, breast can-
cer remains a major public health problem and a major
cause of death for women worldwide [1, 2]. Recent gene
expression profiling studies have shown that this heteroge-
neous disease is composed of five major biological sub-
types: luminal A, luminal B, HER2-enriched, basal-like,
and normal breast-like [3]. The majority of basal-like
breast cancers exhibit a triple-negative phenotype (ERα−,
progesterone receptor-negative (PR−), Her2-neu-negative)
and high frequency of p53 mutations [4]. Triple negative
breast cancer is an aggressive histological subtype with
poor prognosis and high rates of relapse following chemo-
therapy as compared to other subtypes [4, 5]. Neverthe-
less, studies of neoadjuvent chemotherapy suggest that
women with TNBC who have a pathological complete re-
sponse to treatment achieve excellent outcome (Carey LA
2007, Liedtke C 2008). Unfortunately, disease recurrence
is very frequent, and conventional treatments for relapsed
patients are limited. Therefore, there is an urgent unmet
need for the development of novel generation of drugs
with high efficiency and specificity against this particular
group of patients.
ERα is a ligand-activated transcription factor, which
plays major roles in breast carcinogenesis. Indeed, ERα
signaling pathway is one of the most important pathways
in hormone-dependent breast cancer. The amplification
of the ERα coding gene ESR1 is frequent in various
breast tumors as well as in benign and precancerous
breast diseases, suggesting that ESR1 amplification may
be a common mechanism in proliferative breast disease
and a very early genetic alteration in a large subset of
breast cancers [6]. Thereby, it’s reasonable to consider
ERα inhibitors of significant clinical interest.
Several dietary phytochemicals have shown promising
anti-cancer properties, and have been used as thera-
peutic agents against various illnesses for centuries [7].
Curcumin (diferuloylmethane), the major active compo-
nent of the spice turmeric, has been widely used in trad-
itional medicines for thousands of years [8]. Several in
vitro and in vivo studies as well as clinical trials have
shown that curcumin has potent anti-cancer effects, and
safe even at high doses. However, curcumin exhibits
poor aqueous solubility and low absorption in the
gastrointestinal tract, which limits its clinical use [9]. To
bypass this limitation, several curcumin analogues were
synthesized, with the hope to increase the efficacy while
preserving the same safety profile. PAC (4-hydroxy-3-
methoxybenzylidene)-N-methyl-4-piperidone) is a promis-
ing anti-cancer curcumin analogue. Indeed, PAC is 5 times
more efficient than curcumin in inducing apoptosis in
breast cancer cells [10]. In the present study we have shown
that PAC is more stable than curcumin in PBS and in circu-
lating blood. Furthermore, PAC-dependent cytotoxicity is
more potent on ERα− cells than ERα+ cells through
down-regulation of ERα. Moreover, PAC inhibits the
pro-metastatic epithelial-to-mesenchymal transition (EMT)
process in breast cancer cells, with higher efficiency on the
TNBC subtype. Additionally, PAC suppressed the paracrine
procarcinogenic effects of breast cancer cells on breast stro-
mal fibroblasts via suppressing the secretion of two import-
ant cytokines IL-6 and MCP-1.
Methods
Ethics statement
Animal experiments were approved by the King Faisal Spe-
cialist Hospital and Research Center institutional Animal
Care and Use Committee (ACUC) under the RAC pro-
posal # 2080009, and were conducted according to relevant
national and international guidelines. Animals suffered
only needle injection pain and also certain degree of pain/
distress related to the growth/ burden of the tumor. The
euthanasia was performed using cervical dislocation.
Cells and cell culture
The human breast cancer cell lines were all obtained
from the American Type Culture Collection (ATCC).
Cells were cultured following the instructions of the
company. NBF-1 are primary normal breast fibroblasts
developed from tissues obtained from plastic surgery, and
cultured as previously described [11]. All supplements
were obtained from Sigma (Saint Louis, MO, USA) except
for antibiotic and antimycotic solutions, which were ob-
tained from Gibco (Grand Island, NY, USA).
Cellular lysate preparation and immunoblotting
This has been performed as previously described [12].
Antibodies directed against Vimentin (RV202), Twist1,
N-cadherin and interleukin-6 (IL-6) were purchased
from Abcam (Cambridge, MA); Akt, phospho-Akt
(193H12), Erk1/2, phospho-Erk1/2 (THR202/TYR204),
E-cadherin (24E10) and MCP-1 from Cell Signaling
(Danvers, MA); c-Myc from BD Biosciences (San Jose,
CA); Cyclin D1 (HD11), ERα (F-10) and glyceraldehydes-
3-phosphate dehydrogenase (GAPDH, FL-335), were pur-
chased from Santa Cruz (Santa Cruz, CA).
RNA purification and quantitative RT-PCR
Total RNA was purified using the TRI reagent (Sigma)
according to the manufacturer’s instructions, and was
treated with RNase-free DNase before cDNA synthesis
using the Advantage RT Kit (Clontech). For quantitative
RT-PCR, the RT2 Real-Time™ SYBR Green qPCR mas-
termix (Qiagen, UK) was used and the amplifications
were performed utilizing the Bio-Rad iQ5 multicolor
Real time PCR detection system. The melting-curve data
were collected to check PCR specificity, and the amount
of PCR products was measured by threshold cycle (Ct)
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values and the relative ratio of specific genes to GAPDH
for each sample was then calculated. The respective
primers are:




c-MYC: 5’- CTTCTCTCCGTCCTCGGATTCT-3’ and
5’-GAAGGTGATCCAGACTCTGACCTT-3’
Transfection
The pGFP-C-shLenti plasmid bearing ESR1-shRNA or
scrambled shRNA (Origene), were used at 1 μg/ml each
for transfection of 293FT cells. Lentiviral supernatants
were collected 48 h post-transfection. Culture media were
removed from the target cells and replaced with the lenti-
viral supernatant and incubated for 24 h in the presence
of 1 μg/ml polybrene (Sigma-Aldrich). Transduced cells
were selected after 48 h with puromycin (Invitrogen).
Bioavailability of PAC and curcumin
For the bioavailability experiments, normal Balb/c mice
(n = 3×5, 25 g, 3 mice/time point) were intraperitoneally
injected with PAC or curcumin (100 mg/Kg). 400 μL
blood samples were withdrawn directly from the heart
of each mouse into a heparin-rinsed vial at 15, 30, 45, 60
and 120 min post-injection. Each blood sample was cen-
trifuged at 3000 × g for 5 min. The resulting plasma sam-
ple (100 μL) was acidified using hydrochloric acid (HCl
6 N, 10 μL) followed by three times extraction with a mix-
ture of ethyl acetate:propanol (9:1, 1 mL). The extract was
then completely dried and re-dissolved in methanol
(100 μL) before direct injection onto HPLC for analysis.
Using a standard curve of PAC and curcumin, the data
obtained from analyzed samples were utilized to construct
pharmacokinetic curve of PAC/curcumin concentrations
in plasma using the Graph Pad Prism software. Separate
experiments using the same extraction system were car-
ried out to determine extraction efficiency of PAC and
curcumin from plasma and showed a yield of 96 %.
HPLC analyses
Reversed-phase HPLC were performed on Jasco, HPLC
systems using C18 column (10 μm, 4.6 × 250 mm)
(Econosil, Alltech, USA). HPLC was run using a gradient
of 0.1 % TFA in water (solvent A) and 0.1 % TFA in
CH3CN (solvent B) gradient, 0 to 50 % B, 15 min, 50 to
50 % B, 5 min, 50 to 0 % B, 5 min, and 100 to 100 % A,
5 min each at flow rate of 1 mL/min. The HPLC systems
are equipped with a UV detector set at 420 nm, a Flow-
count γ-radioactivity detection system (Bioscan, USA)
and Lauralite analysis program (LabLogic, UK).
Cell migration, invasion and proliferation
These assays were performed as described in detail pre-
viously [13]. Cell migration, invasion and proliferation
were assessed in a real-time, non-invasive, and label-free
manner using the xCELLigence RTCA technology
(Roche). Migration and invasion were assessed as per the
manufacturer’s instructions using the CIM-plate 16.
Briefly, initially 160 μl of cell-free complete media, or
SFM were added to the lower chamber wells and 30 μl of
SFM to the upper chamber wells and plates were incu-
bated for 1 h in the cell incubator to obtain equilibrium.
Subsequently, the background signal was measured and
exponentially growing cells resuspended in 100 μl of SFM
were seeded in the upper chamber wells with a thin layer
of matrigel basement membrane (invasion) or without
(migration). Cells were seeded at 1–3 × 104 cells/well.
After cell addition CIM-plates 16 were incubated for
30 min at room temperature in the laminar flow. Subse-
quently, the plates were locked in the RTCA DP device in
the incubator. Each condition was performed in triplicate.
For proliferation assays, exponentially growing cells in
complete media (0.5–1 × 104/well) were seeded in E-
plates as per manufacturer’s instructions. The rest of the
procedure was the same as for the invasion and migra-
tion assays. Relative cell migration, invasion and prolifer-
ation levels are shown in arbitrary units.
Apoptosis analysis by annexin V/flow cytometry
Cells were either not treated or challenged with PAC or
curcumin, and then harvested, centrifuged and stained
with propidium iodide (PI) and Alexa Flour 488 annexin
V (Molecular Probes, Eugene, OR, USA) as previously
described [14].
Protein arrays
SFCM were applied to RayBio the human cytokine array
5 (AAH-CYT-5, RayBiotech, Inc (Norcross, GA, USA)
as per manufacturer’s instructions. Signal densities were
assessed with the ImageJ software, and data analysis was
carried out following the Array protocol’s instructions.
Tumor xenografts
Breast cancer xenografts were created in nude mice by
subcutaneous injection of MDA-MB-231 cells, and then
the animals were treated with PAC (100 mg/Kg) or
DMSO as previously described [10].
Statistical analysis
Student’s t-test was used for statistical analysis and
p values ≤ 0.05 were considered as statistically significant.
Conditioned media
Cells were cultured in medium without serum for 24 h,
and then media were collected and briefly centrifuged,
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and cells were counted. The resulting supernatants
(SFCM) were used either immediately or were frozen
at −80 °C until needed. SFCM were diluted, when neces-
sary, based on the cell counts.
Results
PAC is more stable than curcumin in PBS and circulating
blood
To compare the stability of curcumin with that of PAC,
we have first studied the stability of both molecules in
phosphate buffer (0.1 M, pH 7.4). PAC and curcumin
were incubated in PBS for different periods of time (0, 5,
30 min), and then were analyzed by HPLC. Both PAC
and curcumin were instable in PBS at 37 °C, but PAC
showed higher stability (Fig. 1a). Indeed, after 30 min of
incubation more than 90 % of curcumin was decom-
posed, while only 60 % of PAC was decomposed (Fig. 1b).
This indicates that after 30 min of incubation PAC was
4 times more stable than curcumin in PBS.
In order to test the bioavailability of curcumin and
PAC in animals, normal Balb/c mice (n = 30) were intra-
peritonealy injected with PAC or curcumin (100 mg/Kg).
400 μL blood samples were withdrawn directly from the
heart of each mouse at 15, 30, 45, 60 and 120 min post-
injection. The resulting plasma extracts were completely
dried and re-dissolved in methanol (100 μL) before in-
jection onto HPLC for analysis. Figure 1c shows that the
amount of PAC presents in plasma at 15 min post-
injection reached 35 μg/mL, while the level of curcumin
was only 10.3 μg/mL. The level of PAC further increased
in blood reaching its maximum level (40 μg/mL) 45 min
post-injection, and dropped to 10 μg/mL at 60 min post-
injection, then remained relatively constant during the
following 60 min (Fig. 1c). On the other hand, the level
of curcumin decreased in a time-dependent manner
reaching a level as low as 0.3 μg/mL 120 min post-
injection. This shows that 25 % of the injected PAC was
still in blood 2 h post-injection, and that PAC is 30 times
more stable than curcumin in circulating blood.
PAC induces apoptosis in breast cancer cells with higher
efficiency on basal-like cells
To measure the extent and the nature of cell death induced
by PAC on various breast cancer cell lines, the
fluorochrome-conjugated annexin V/PI stain test was used
and cells were analyzed by a flow cytometer. Different cell
lines were used including basal-like, ERα− (MDA-MB-231,
MDA-MB-468, BT-20, and BT-549), luminal, ERα+ (MCF-
7, T-47D and BT-474), and HER2-enriched, ERα− (SK-BR-
3). Sub-confluent cells were treated either with DMSO
(used as control) or with PAC (10 μM) for 72 h. Figure 2a
shows the presence of four different cell populations after
the double staining annexin V/PI and sorting by flow cy-
tometry: live cells (normal) (annexin V-/PI-), early apop-
totic cells (Apo) (annexin V+/PI-), late apoptotic cells (Late
apo) (annexin V+/PI+) and necrotic cells (Necrotic)
(annexin V-/PI+). Importantly, PAC induced cell death
mainly by apoptosis in all breast cancer cells (Fig. 2a).
Figure 2b presents cell death of different cell lines after
treatment with PAC as percentages relative to DMSO-
Fig. 1 PAC is more stable than curcumin. a Curcumin and PAC structures. Both molecules were incubated in phosphate buffer (0.1 M, pH 7.4) for
different periods of time, and then were analyzed by HPLC. The arrows indicate the peaks corresponding to the intact PAC and curcumin
molecules. b Histogram showing the proportion of the remaining molecules. Error bars represent means ± SD from three different experiments,
*, P ≤ 0.01. c Balb/c mice were intraperitonealy injected with PAC and curcumin (100 mg/Kg). Blood samples were withdrawn directly from the
heart of each mouse at the indicated periods of time. The resulting plasma extracts were dried and re-dissolved in methanol before injection onto
HPLC for analysis. The error bars represent means +/- SD
Al-Howail et al. BMC Cancer  (2016) 16:540 Page 4 of 11
treated cells. The real effect of PAC was obtained by dis-
carding the proportion of dead cells obtained in the con-
trol samples from the treated ones for each cell line. In
addition, the proportion of total cell death was consid-
ered as the sum of necrosis and both early and late
apoptosis. 80–90 % of basal-like cells (MDA-MB-231,
MDA-MB-468, BT-20, and BT-549) and about 65 % of
HER2-enriched cells (SK-BR-3) underwent cell death in
response to PAC (Fig. 2b). While in luminal cells, only
45 % of MCF-7 cells and 25 % of T-47D cells died upon
PAC treatment (Fig. 2b). This indicates that PAC is cyto-
toxic against various types of breast cancer cells, and its
effect is more potent on the ERα− subtype.
Specific ERα down-regulation sensitizes breast cancer
cells to PAC
To explore the role of ERα in PAC-dependent induction
of apoptosis, we knocked-down the ESR1 gene in MCF-
7 cells using specific ESR1-shRNA, and a scrambled se-
quence was used as control. Figure 3a shows strong ERα
down-regulation by the ESR1-shRNA1, while ESR1-
shRNA2 and ESR1-shRNA3 had only marginal effects.
Similar effect was observed on the ERα target c-Myc
(Fig. 3a). Subsequently, these cells were either sham-
treated (DMSO) or challenged with PAC (10 μM) for
3 days, and then cell death was assessed by AnnexinV/PI
as described above. Figure 3b and c shows that while
PAC triggered apoptosis in only about 35 % of cells bear-
ing control-shRNA, ESR1-shRNA2 or ESR1-shRNA3,
the proportion of apoptotic cells reached 70 % in MCF-7
cells expressing ESR1-shRNA1. This shows that ERα
down-regulation plays a major role in PAC-induced
apoptosis in breast cancer cells.
PAC down-regulates ERα, c-Myc and cyclin D1
We then set out to test the effect of PAC on the expres-
sion of ERα in both types of cells (ERα -positive and –
negative). To this end, MDA-MB-231 and MCF-7 cells
were exposed to PAC (10 μM) and were harvested after
different periods of time (0, 8, 24, 48, 72 h). Cell lysates
were prepared and 100 μg/ml of proteins were used for
immunoblotting analysis using specific anti- ERα anti-
body, and GAPDH was utilized as internal control. The
level of ERα decreased in both cell lines, but became un-
detectable after 24 h of treatment in MDA-MB-231 cells,
while a significant amount of the protein was still
present in MCF-7 cells even after 72 h of treatment
(Fig. 4a). The ERα protein is a well-known positive regu-
lator of cyclin D1 and c-Myc, two important apoptosis
modulators in breast cancer cells [15]. Therefore, we in-
vestigated the effect of PAC on the expression of these
two proteins. Figure 4a shows that the levels of both
proteins started to decrease after 24 h of treatment and
continue to decline in a time-dependent manner in
MDA-MB-231. On the other hand, the effect of PAC on
cyclin D1 and c-Myc was only marginal in MCF-7 cells
(Fig. 4a). To confirm this finding, we tested the effect of
PAC on CCND1 and c-MYC mRNAs. MDA-MB-231
and MCF-7 cells were either sham-treated (DMSO) or
challenged with PAC (10 μM) for 24 h and total RNA
was purified and used for amplification by quantitative
RT-PCR using specific primers. Figure 4b shows that
while PAC strongly down-regulated both genes in MDA-
MB-231 cells, it increased the level of c-MYC and had
only marginal effect on cyclin D1 in MCF-7 cells. This
confirms the strong effect of PAC on ERα in ERα− breast
cancer cells and indicates that this gene as well as its tar-
gets c-MYC and CCND1 might play important roles in
the response of these cells to PAC. To further validate
these findings we tested the effect of PAC on these three
genes in tumor xenografts formed subcutaneously in
nude mice upon injection of MDA-MB-231 [10]. The
immunoblotting shows PAC-dependent down-regulation
of the 3 genes in xenogratft tissues isolated from PAC-
treated animals as compared to control animals treated
with DMSO (Fig. 4c).
Fig. 2 PAC triggers apoptosis more efficiently in ERα-negative than
in ERα-positive breast cancer cells. Cells were either sham-treated or
challenged with PAC (10 μM) for 72 h, and then cell death was
assessed by annexin V/PI in association with flow cytometry. a Charts.
b Histogram showing the proportion of cell death (apoptosis +
necrosis) in each cell line. Error bars represent means ± SD from three
different experiments, *, P ≤ 0.05
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PAC suppresses the epithelial-to-mesenchymal transition
process both in vitro and in vivo
Since estrogen receptor signaling plays a role in the pro-
metastatic epithelial-to-mesenchymal transition (EMT)
process, we sought to investigate the effect of PAC on EMT
in both ERα+and ERα− cells. To this end, MDA-MB231
and MCF-7 cells were either sham-treated or challenged
with PAC (10 μM), and then cell proliferation was assessed
using the xCELLigence RTCA technology utilizing the E-
plates. Figure 5a shows strong PAC-dependent inhibition of
cell proliferation of both MDA-MB-231 and MCF-7 cells,
with a more pronounced effect on the ERα− cells.
Next, we investigated the effect of PAC on the migration/
invasion abilities using the xCELLigence RTCA technology
utilizing CIM-plate 16. Figure 5b shows that PAC inhibits
the migration and the invasion capabilities of both cell
lines, with an effect more pronounced on the ERα− MDA-
MB-231 cells as compared to the ERα+ MCF-7 cells.
To elucidate the molecular basis of this decrease in
the migration/invasion abilities, we tested the effect of
PAC on the pro-invasive/migratory protein kinases
ERK1/2 and AKT. Therefore, MDA-MB-231 and MCF-7
cells were either sham-treated or challenged with PAC
(10 μM) for 24 h, and then cell lysates were prepared
and total levels as well as the phosphorylated/active
forms of these two proteins were assessed by immuno-
blotting. Figure 5c shows strong PAC-dependent inhib-
ition of both protein kinases AKT and ERK1/2 in both
Fig. 3 ERα down-regulation potentiates the pro-apoptotic effect of PAC. MCF-7 cells were transfected with vectors containing 3 different
ESR1-shRNA sequences (1, 2, 3) or a scrambled sequence (Scbl). a Cell lysates were prepared and used for immunoblotting analysis using
antibodies against the indicated proteins. b Cells were treated with PAC (10 μM) and the proportion of apoptotic cells was determined using
annexinV/PI-Flow cytometry. c Histogram, Error bars represent means ± S.D from three different experiments, *, P ≤ 0.005
Fig. 4 PAC down-regulates ERα and its targets C-Myc and cyclin D1. a Cells were challenged with PAC (10 μM) for the indicated periods of time,
and then cell lysates were prepared and used for immunoblotting analysis utilizing specific antibodies against the indicated proteins. b Cells
were either sham-treated (DMSO) or challenged with PAC (10 μM) for 24 h, and then total RNA was extracted and used for qRT-PCR using
specific primers for the indicated genes. Error bars represent means ± S.D from three different experiments, *, P ≤ 0.05. c Nude mice bearing
sub-cutaneous humanized tumor xenografts were treated with DMSO or PAC, and then cell lysates were prepared from excised tumors and
used form immunoblotting utilizing specific antibodies against the indicated proteins
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cell lines, with a higher effect on MDA-MB-231 cells. In-
deed, the inhibition of ERK1/2 was very strong in the
TNBC cells (Fig. 5b). Since the activation of these two
protein kinases is part of EMT, we investigated the pos-
sible PAC-dependent inhibition of this pro-metastatic
process, through testing the effect on the expression of
specific mesenchymal and epithelial markers by im-
munoblotting. Figure 5c shows clear PAC-dependent
up-regulation of E-cadherin in MCF-7 cells, while the
levels of all tested mesenchymal markers (N-cadherin,
vimentin and Twist-1) were reduced in both cell lines,
but the effect was more pronounced in MDA-MB-231
cells as compared to MCF-7 cells. Interestingly, similar
results were obtained in vivo on tumor xenografts upon
sub-cutaneous injection of MDA-MB231 cells in nude
mice followed by intraperitoneal treatment with PAC
(100 mg/Kg) (Fig. 5d). Indeed, PAC inhibited the two
important protein kinases AKT and ERK1/2 and also up-
regulated E-cadherin, while it down-regulated the mesen-
chymal markers N-cadherin, vimentin and twist1 (Fig. 5d).
Together, these results indicate that PAC suppresses the
EMT process in breast cancer cells both ERα -positive
and -negative, with a more potent effect on ERα- cells.
PAC inhibits the expression/secretion of the pro-
metastatic MCP-1 and IL-6 cytokines
Human cytokine antibody arrays were used to detect the
differentially expressed cytokines in the conditioned
media obtained from MDA-MB-231 cells either sham-
treated (DMSO) or challenged with PAC (10 μM). This
experiment showed the differential expression of several
cykokines, including IL-6, MCP-1, IL-5 and angiogenin
(Fig. 6a and b). The effect on IL-6 and MCP-1 is of great
importance since these two cytokines play important
Fig. 5 PAC suppresses EMT in breast cancer cells and tumor xenografts. a Cells were seeded in E-16 plates for 24 h, and then were either
sham-treated (DMSO) or exposed to PAC (10 μM) for the indicated periods of time. Cell proliferation was monitored in real time using the
RTCA-DP xCELLigence System. b Cells were exposed to DMSO or PAC (10 μM) for 24 h, and then were seeded in the CIM-plate with SFM in
the upper wells separated by 8 micron pore size PET membrane with thin layer of matrigel basement membrane matrix (invasion) or without
(migration). The lower chambers contained complete media as chemoattractant. Cells were incubated in normal culture conditions for 24 h and
the migration/invasion were determined using the real time RTCA-DP xCELLigence System. Error bars represent means ± S.D from 3 different
experiments; *, P ≤ 0.001. c Cells were either sham-treated (DMSO) or challenged with PAC (10 μM) for 24 h, and then cell lysates were prepared
and used for Immunoblotting analysis using antibodies against the indicated proteins. d Figure legends as in Fig. 4c
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roles in the spread of various types of cancer, including
breast carcinomas [16]. Therefore, we tested the effect of
PAC on the expression of these two cytokines at the
protein level. The immunoblotting analysis shows strong
PAC-dependent down-regulation of both IL-6 and
MCP-1 in MDA-MB-231 cells (Fig. 6c).
PAC suppresses the paracrine effects of breast cancer
cells on breast stromal fibroblasts
After showing PAC-dependent inhibition of IL-6/MCP-1
expression and secretion from breast cancer cells we
sought to test the effect of PAC on the paracrine effects of
these cells on breast stromal fibroblasts. To this end,
MDA-MB-231 cells were first either sham-treated (DMSO)
or challenged with PAC (10 μM) for 24 h. Subsequently,
cells were cultured in serum-free medium (SFM) for 24 h,
and then serum-free conditioned media (SFCM) were col-
lected and utilized to challenge normal breast stromal
fibroblast cells NBF-1 for 24 h. Proliferation, migration and
invasion of stromal fibroblasts were assessed with the
xCELLigence RTCA technology. Figure 7a shows PAC-
dependent inhibition of the paracrine effects of MDA-MB-
231 cells on the proliferation rate of fibroblast cells.
Similarly, media conditioned with PAC-treated MDA-MB-
231 cells strongly suppressed the migration/invasion abil-
ities of breast stromal fibroblasts (Fig. 7b). Together, these
results indicate that PAC inhibits the pro-metastatic effects
of the highly invasive breast cancer cells MDA-MB-231.
Discussion
Triple-negative breast cancers are poorly differentiated,
highly malignant and have a poor outcome. Duration of
response is usually short, with rapid relapse very com-
mon and median survival of advanced disease of just
13 months, which is much less than the median duration
of survival observed in other advanced subtypes [17, 18].
This made TNBC one of the most attractive areas of re-
search in oncology [19, 20].
We have shown here that the newly synthesized curcu-
min analogue PAC is 4 times more stable than curcumin
in PBS and 30 times more stable than curcumin in circulat-
ing blood in mice (Fig. 1). This higher bioavailability of
PAC is of great importance since the low bioavailability of
curcumin limits its potential use in the clinic. Additionally,
we present strong evidence that PAC is a potent anti-
breast cancer agent with the strongest effects on the TNBC
subtype cells. Indeed, PAC exhibited higher cytotoxicity
against different TNBC cells (MDA-MB-231, MDA-MB-
468, BT-20 and BT-549) than luminal cells (MCF-7 and T-
47D). Likewise, PAC inhibited the proliferation of breast
cancer cells with higher effect on ERα−cells than on ERα+
cells. Interestingly, when ERα was down-regulated in
MCF-7 cells with specific shRNA, the pro-apoptotic effect
of PAC was doubled. This clearly showed that high expres-
sion of ERα limited PAC cytotoxic effects on breast cancer
cells, and we hypothesized that PAC-dependent apoptosis
could be mediated through ERα down-regulation. There-
fore, we tested the effect of PAC on the expression of ERα
in cells that express high and low level of this receptor, and
have shown that PAC reduced ERα level in both types of
cells, but in the ERα− cells ERα became undetectable, while
its level was still high in ERα+ cells despite its diminution.
This provided a meaningful explanation to the higher effect
of PAC on ERα−cells, and corroborated the result obtained
Fig. 6 PAC inhibits the expression/secretion of IL-6 and MCP-1. SFCM from MDA-MB-231 cells either sham treated (DMSO) or challenged with
PAC (10 μM) for 24 h were collected and applied onto Human Cytokine Antibody Array membrane. a Blots, the rectangles indicate the spots
corresponding to IL-6 and MCP-1, while the arrows indicate differentially expressed cytokines. b Histogram showing secretion levels of the
indicated cytokines upon quantification. Error bars represent means ± S.D, *, P ≤ 0.05. c Cells were exposed to DMSO or PAC, and then cell lysates
were prepared and used for immunoblotting analysis using specific antibodies against the indicated proteins
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by specific down-regulation of ERα in cells that express
this receptor. This also confirmed our previous results
showing that expression of the receptor coding gene ESR1
in ERα− breast cancer cells increased their resistance to
PAC [10]. Together, these results indicate that PAC-related
induction of apoptosis in breast cancer cells depends on
the cellular level of ERα. In fact, various laboratory studies
demonstrated that reduced estrogen levels induced apop-
tosis [21]. A cyclopentenone derivative (CTC-35) was also
shown to have potent proapoptotic activity in ERα− breast
cancer cells [22]. Furthermore, green tea EGCG decreased
the proliferation rates of breast cancer cells through strong
down-regulation of ERα [23].
PAC-dependent down-regulation of ERα in MDA-MB-
231 cells was accompanied with a strong decrease in the
level of ERα main targets c-Myc and cyclin D1, both in
vitro and in vivo. However, c-Myc and cyclin D1 were not
down-regulated in MCF-7 cells, and the c-MYC mRNA
was rather up-regulated after 24 h of PAC treatment
(Fig. 4b). This difference in the c-MYC mRNA and protein
levels upon PAC treatment could result from translational
of post-translational regulatory process in MCF-7 cells. c-
MYC and cyclin D1 are two major oncogenes, which confer
proliferative and anti-apoptosis capacities to breast cancer
cells [15], and are associated with altered sensitivity to
endocrine therapy [24]. The c-Myc protein plays a major
role in the apoptotic response of breast cancer cells [25].
This protein has been found overexpressed in 45 % breast
tumors [26]. Cyclin D1 is an oncogene that is overex-
pressed in about 50 % of all breast cancer cases [27], and its
down-regulation is an important target in breast cancer
therapy [28]. Therefore, PAC-related targeting of these two
oncogenes could be of great therapeutic value.
In addition, we have shown that PAC suppresses the
EMT process in both ERα+ and ERα− cell lines, with a
higher effect on ERα-negative cells (Fig. 5). EMT is cur-
rently considered as pivotal event in the initial step of the
metastatic cascade that allows cells to acquire migratory, in-
vasive and stem-like properties [29]. Evolving evidence indi-
cates that ERα signaling can directly regulate EMT-related
transcriptional factors, indicating that ERα might be a key
regulator of the EMT program [30–33]. PAC inhibited the
migration/invasion abilities of breast cancer cells through
inhibiting the ERK1/2 and AKT protein kinases, and
repressed the mesenchymal markers vimentin and N-
cadherin. Similar effects were also observed in vivo on
tumor xenografts, wherein PAC increased the expression
of E-cadherin and repressed N-cadherin, vimentin, AKT
and Twist1. Similarly, it has been previously shown that
curcumin plays an important role in the inhibition of
lipopolysaccharide-induced EMT in breast cancer cells
through the down-regulation of NF-kB-Snail activity [34].
In addition to their high migratory and invasiveness
capacities, ERα− cells secrete high amounts of pro-
metastatic cytokines such as IL-6 and MCP-1, which can
activate stromal cells including fibroblasts [16, 35, 36].
Interestingly, PAC reduced the secreted levels of several
cytokines including IL-6 and MCP-1 from MDA-MB-
231 cells. This repressed the paracrine pro-replicative
and -invasive/migratory effects of these highly invasive
cells on breast stromal fibroblasts. This shows the ability
of PAC in inhibiting the pro-metastatic capabilities of
MDA-MB-231 cells. Indeed, there exists abundant evi-
dence demonstrating that active stromal fibroblasts play
major roles in breast cancer progression and spread [37].
These cells escort cancer cells through the whole car-
cinogenesis process. Therefore, targeting active stromal
fibroblasts or blocking their cross-talk with cancer cells
is a promising therapeutic approach [38, 39].
Conclusions
We have shown here that PAC has better bioavailability
than curcumin. Moreover, we present clear evidence that
PAC down-regulates ERα and triggers apoptosis in breast
Fig. 7 PAC suppresses the paracrine procarcinogenic effects of breast cancer cells. SFCM from MDA-MB-231 cells either exposed to DMSO
(DMSO-MDA-SFCM) or challenged with PAC (10 μM) (PAC-MDA-SFCM) was used for indirect co-culturing of NBF-1 fibroblasts cells for 24 h, and
then cell proliferation (a) as well as migration/invasion (b) were assessed using the real time RTCA-DP xCELLigence System as described in Fig. 4.
Error bars represent means ± S.D from three different experiments; *, P ≤ 0.001
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cancer cells with higher efficiency on receptor negative
cells. Furthermore, PAC suppressed the prometastatic fea-
tures of the invasive breast cancer cells by suppressing
EMTand the paracrine effect on breast stromal fibroblasts.
This makes PAC as a valuable candidate for the future ar-
mada against the devastating TNBC type of tumors.
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